# TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing

> **NCT00938899** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 55 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** TMC435350; Placebo

## Key facts

- **NCT ID:** NCT00938899
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00938899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00938899, "TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00938899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*